Adagio Medical Holdings, Inc. (ADGM)

US — Healthcare Sector
Peers: NXGL  LPTX  ENTO  NXL  MGRX  COCH  IINN  MODD  CASI  RNTX 

Automate Your Wheel Strategy on ADGM

With Tiblio's Option Bot, you can configure your own wheel strategy including ADGM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ADGM
  • Rev/Share 0.0027
  • Book/Share 0.5634
  • PB 2.3784
  • Debt/Equity 2.0516
  • CurrentRatio 2.5035
  • ROIC -2.7232

 

  • MktCap 20611297.0
  • FreeCF/Share -1.3507
  • PFCF -0.9921
  • PE -0.3387
  • Debt/Assets 0.4956
  • DivYield 0
  • ROE -2.0711

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Adagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium
ADGM
Published: October 10, 2025 by: Business Wire
Sentiment: Neutral

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced preliminary acute (within 7 days) safety and efficacy results from the Adagio's FULCRUM-VT Study evaluating Ultralow Temperature Cryoablation (“ULTC”) for the treatment of Sustained Monomorphic Ventricular Tachycardia (“SMVT”) in patients with both ischemic and nonischemic.

Read More
image for news Adagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium
Adagio Medical Announces Strategic Restructuring to Accelerate US Pivotal IDE Trial and Product Innovation
ADGM
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced a corporate restructuring and realignment of resources to prioritize its FULCRUM-VT US pivotal investigational device exemption (“Pivotal IDE”) clinical trial activities and its new product design optimization program. “After a comprehensive strategic review, we are doubling down on the pri.

Read More
image for news Adagio Medical Announces Strategic Restructuring to Accelerate US Pivotal IDE Trial and Product Innovation

About Adagio Medical Holdings, Inc. (ADGM)

  • IPO Date 2024-07-23
  • Website https://adagiomedical.com
  • Industry Medical - Devices
  • CEO Todd Usen
  • Employees 80
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.